News

Cybrexa Therapeutics in the Hartford Courant

“It’s really like a heat-seeking missile toward tumors,” Yale physician-scientist and Cybrexa’s chief scientific adviser, Dr. Ranjit Bindra, tells the Hartford Courant. “I know it sounds over the top but we’re really re-writing the rules of what makes a drug good and...

read more

Cybrexa in HartfordBusiness.com

HartfordBusiness.com recently published a Q&A with Cybrexa's Per Hellsund about fundraising, and finding success in biotech startups. Read the full article here....

read more

Cybrexa Therapeutics Secures $6 Million in Series B Financing

Financing supports development of new class of cancer therapies. New Haven, Conn., June __, 2017 Cybrexa Therapeutics, a start-up cancer therapeutics company, announced today that it has secured a Series B round of financing in the amount of $6 million. Connecticut...

read more

Below are links to coverage of the high-impact DNA repair research findings by our Scientific Founders.

 

http://news.yale.edu/2016/10/26/yale-scientists-edit-gene-mutations-inherited-form-anemia

http://medicine.yale.edu/news/article.aspx?id=14561

https://yalealumnimagazine.com/articles/4429-a-breakthrough-in-gene-therapy

http://www.nature.com/nature/journal/v542/n7642/full/542394c.html

http://cancerdiscovery.aacrjournals.org/content/early/2017/02/21/2159-8290.CD-NB2017-026

http://www.businessinsider.com/new-study-brain-tumors-2017-1

http://www.bioworld.com/content/exploiting-idh-mutations-could-be-therapeutic-approach-0

http://yaledailynews.com/blog/2017/02/14/study-points-to-potential-new-brain-cancer-treatment/

https://medicalxpress.com/news/2017-02-scientists-key-defect-brain-tumor.html

http://www.onclive.com/sap-partner/cancer-centers/yale-cancer/yale-scientists-identify-key-defect-in-brain-tumor-cells

https://www.biosciencetechnology.com/news/2017/02/brain-tumor-cells-sensitive-fda-approved-ovarian-cancer-drug-study-finds

https://www.sciencedaily.com/releases/2017/02/170202141211.htm

http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-02-01-ovarian-cancer-drug-could-target-gene-fault-in-brain-tumours

https://www.labroots.com/trending/cancer/5276/key-genetic-defect-brain-tumor-cells

http://healthmedicinet.com/yale-researchers-find-potential-new-way-to-combat-brain-cancer/

http://www.practiceupdate.com/content/2-hydroxyglutarate-produced-by-neomorphic-idh-mutations-induces-parp-inhibitor-sensitivity/49674/37/12/1 

https://www.linkedin.com/pulse/brain-tumor-cells-sensitive-fda-approved-ovarian-cancer-focil

http://www.healalerts.com/article/57069

http://www.bullfax.com/?q=node-researchers-yale-have-taken-steps-toward-%E2%80%98completely-un

http://www.onclive.com/conference-coverage/aacr-2017/function-of-idh-mutations-can-be-exploited-by-parp-inhibitors-instead-of-idh-inhibitors

http://www.targetedonc.com/news/exploiting-dna-repair-deficiency-in-idhmutant-brain-tumors-likely-an-improved-treatment-strategy

https://www.cancer.gov/news-events/cancer-currents-blog/2017/idh-mutation-parp

http://blog.aacr.org/aacr-annual-meeting-2017-challenging-the-dogma-of-treating-idh-mutant-cancers-with-idh-inhibitors/

https://f1000.com/prime/727261055

5 Science Park 395 Winchester Ave. New Haven, CT 06511 (860) 717-2731